← Back to Dental References     ↑ View All References

Medication-Related Damage to Oral Hard and Soft Tissues References

  1. Abdollahi, M., Rahimi, R., & Radfar, M. (2008). Current opinion on drug-induced oral reactions: A comprehensive review. The Journal of Contemporary Dental Practice, 9, 1–15.
  2. Aimetti, M., Romano, F., Marsico, A., & Navone, R. (2008). Non-surgical periodontal treatment of cyclosporin A-induced gingival overgrowth: immunohistochemical results. Oral Disease, 14, 244–250.
  3. Allen, M.R. & Burr, D.B. (2009). The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data. Journal of Oral and Maxillofacial Surgery, 67, 61–70.
  4. American Dental Association (ADA). (2005). Fluoridation facts. Retrieved June 22, 2009, from http://web.archive.org/web/20070307065553/http://www.ada.org.au/media/Fluoridenow/Documents/AmDA+fluoridation_factsRO.pdf
  5. American Dental Association (ADA). (2009) Fluoride and infant formula frequently asked questions (FAQ). Retrieved June 22, 2009, from http://www.ada.org/public/topics/fluoride/infantsformula_faq.asp#2
  6. Avar, A., Elli, M., Darka, O., & Pinarli, G. (2007). Long-term effects of chemotherapy on caries formation, dental development, and salivary factors in childhood cancer survivors. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 104, 781–789.
  7. 7. Bahamondes, C. & Godoy, J. (2007). Cyclo­sporine-induced gingival hyperplasia: report of one case]. Revista Medica de Chile, 135, 370–374.
  8. Benso, J. & Daugherty, K.K. (2007). Botulinum toxin A in the treatment of sialorrhea. The Annals of Pharmacotherapy, 41, 79–85.
  9. Bertassoni, L.E., Martin, J.M., Torno, V., Vieira, S., Rached, R.N., & Mazur, R.F. (2008). In-office dental bleaching and enamel microabrasion for fluorosis treatment. The Journal of Clinical Pediatric Dentistry, 32, 185–187.
  10. Boyce, H.W. & Bakheet, M. R. (2005). Sialorrhea: A review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. Journal of Clinical Gastroenterology, 39, 89–97.
  11. Browne, D., Whelton, H., & O’Mullane, D. (2005). Fluoride metabolism and fluorosis. Journal of Dentistry, 33, 177–186.
  12. Butler, D. & Ilse, J. (2009, August 24). Fixed drug eruptions. Retrieved May 10, 2009, from http://emedicine.medscape.com/article/1336702-overview
  13. Cohen, D. & Bhattacharyya, I. (2008). Case of the month: Drug-induced hyperplasia. Todays FDA, 20, 25–27.
  14. de Almeida, V., Grégio, A.M., Machado, M.A., de Lima, A.A., & Azevedo, L.R. (2008). Saliva composition and functions: A comprehensive review, 9, 72–80
  15. Durso, S.C. (2008). Oral manifestations of disease (chap. 32). In A. Fauci, E. Braunwald, D. Kasper, S. Hauser, D. Longo, J. Jameson, & J. Loscalzo (Eds.), Harrison’s principles of internal medicine. New York: McGraw-Hill. Retrieved May 10, 2009, from http://www.accessmedicine.com/content.aspx?aid=2862909
  16. Edwards, B.J., Hellstein, J.W., Jacobsen, P.L., Kaltman, S., Mariotti, A., & Migliorati, C.A. (2008). American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs. Journal of the American Dental Association, 139, 1674–1677.
  17. Edwards, B.J. & Migliorati, C.A. (2008). Osteoporosis and its implications for dental patients. Journal of the American Dental Association, 139, 545–552.
  18. Fujimori, Y., Maeda, S., Saeki, M., Morisaki, I., & Kamisaki, Y. (2001). Inhibition by nifedipine of adherence- and activated macrophage-induced death of human gingival fibroblasts. European Journal of Pharmacology, 9, 95–103.
  19. Gonsalves, W.C., Chi, A.C., Neville, B.W. (2007). Common oral lesions: Part II – Masses and neoplasia. American Family Physician, 15, 75, 509–512
  20. Grewal, V.S. & Fayans, E.P. (2008). Bisphosphonate-associated osteonecrosis: A clinician’s reference to patient management. Todays FDA, 20, 38–41, 43–46.
  21. Guggenheimer, J. & Moore, P.A. (2003). Xerostomia: Etiology, recognition and treatment. Journal of the American Dental Association, 134, 61–69.
  22. Hatch, C.L. (2005). Pigmented lesions of the oral cavity. Dental Clinics of North America, 49, 185–201.
  23. Hellstein, J.W. & Marek, C.L. (2006). Bisphosphonate induced osteochemonecrosis of the jaws: An ounce of prevention may be worth a pound of cure. Special Care in Dentistry, 26, 8–12.
  24. Henke Yarbro, C., Goodman, M., & Hansen Frogge, M. (Eds.). (2004). Cancer Symptom Management (3rd ed.). Sudbury, MA: Jones and Bartlett Publishers. Retrieved May 10, 2009, from http://books.google.com/books?id=oMzhfkVZBDYC&printsec=frontcover&ie=ISO-8859-1&output=html
  25. Hockstein, N.G., Samadi, D.S., Gendron, K., & Handler, S.D. (2004). Sialorrhea: A management challenge. American Family Physician, 69, 2628–2634.
  26. Holmstrup P., Vedtofte P., Reibel J., & Stoltze K. (2006). Long-term treatment outcome of oral premalignant lesions. Oral Oncology, 42, 461–474.
  27. Hölttä, P., Hovi, L., Saarinen-Pihkala, U.M., Peltola, J., & Alaluusua, S. (2005). Disturbed root development of permanent teeth after pediatric stem cell transplantation: Dental root development after SCT. Cancer, 1, 103, 1484–1493.
  28. Hong, L., Levy, S.M., Warren, J.J., Broffitt, B., Cavanaugh, J. (2006). Fluoride intake levels in relation to fluorosis development in permanent maxillary central incisors and first molars. Caries Research, 40, 494–500.
  29. Hugentobler, M. & Richter, M. (2006). A proposed algorithm for medicodental care of patients treated with bisphosphonates. Revue de Stomatologie et de Chirurgie Maxillo-Faciale, 107, 441–444.
  30. Issa, Y., Duxbury, A.J., Macfarlane, T.V., & Brunton, P.A. (2005). Oral lichenoid lesions related to dental restorative materials. British Dental Journal, 198, 361–366.
  31. Jones, J.A., Avritscher, E.B., Cooksley, C.D., Michelet, M., Bekele, B.N., & Elting, L.S. (2006). Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Supportive Care in Cancer, 14, 505–515.
  32. Jordan R. & Lewis M. A color handbook of oral medicine (1st ed.), New York: Thieme/Manson. 2004.
  33. Kalmar, J. (2009, March 11). Oral manifestations of drug reactions. Retrieved May 10, 2009, from http://emedicine.medscape.com/article/1080772-overview
  34. Kataoka, M., Kido, J., Shinohara, Y., & Nagata, T. (2005). Drug-induced gingival overgrowth: A review. Biological & Pharmaceutical Bulletin, 28, 1817.
  35. Kauzman, A., Pavone, M., Blanas, N., & Bradley, G. (2004). Pigmented lesions of the oral cavity: review, differential diagnosis, and case presentations. Journal (Canadian Dental Assocociation), 70, 682–683.
  36. Khan, A.A., Sándor, G.K., Dore, E., Morrison, A. D., Alsahli, M., & Amin, F. (2008). Canadian Association of Oral and Maxillofacial Surgeons. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. The Journal of Rheumatology, 35, 1391–1397.
  37. Kozyreva, O. & May, S. (2007, July 18). Hairy Leukoplakia. Retrieved May 10, 2009, from http://emedicine.medscape.com/article/279269-overview
  38. Lafzi, A., Farahani, R.M., & Shoja, M.A. (2007). Phenobarbital-induced gingival hyperplasia. The Journal Contemporary Dental Practice, 8, 50–56.
  39. Lam, D.K., Sandor, G.K., Holmes, H.I., Evans, A.W., & Clokie, C.M. (2007). A review of bisphosphonate-associated osteonecrosis of the jaws and its management. Journal (Canadian Dental Association), 73, 417–422.
  40. Laudenbach, J.M. & Epstein, J.B. (2009). Treatment strategies for oropharyngeal candidiasis. Expert Opinion on Pharmacotherapy, 10, 1413–1421.
  41. Lodi, G., Sardella, A., Bez, C., Demarosi, F., & Carrassi, A. (2006). Interventions for treating oral leukoplakia. Cochrane Database Systematic Review, 18, CD001829.
  42. Malden, N.J. & Pai, A.Y. (2007). Oral bisphosphonate associated osteonecrosis of the jaws: Three case reports. British Dental Journal, 203, 93–97.
  43. Markiewicz, M.R., Margarone, J.E., Campbell, J.H., & Aguirre, A. (2005). Bisphosphonate-associated osteonecrosis of the jaws: A review of current knowledge. Journal of the American Dental Association, 136, 1669–1674.
  44. Mishra, M., Mohanty, J., Sengupta, S., & Tripathy S. (2005). Epidemiological and clinicopathological study of oral leukoplakia. Indian Journal of Dermatology, Venereology and Leprology, 71, 161–165
  45. National Institutes of Health (NIH) Consensus Development Conference Statement. (1989). Oral Complications of Cancer Therapies: Diagnosis, Prevention, and Treatment. NIH Consensus Statement, 7, 1–11.
  46. Pankhurst, C.L. (2009). Candidiasis (oropharyngeal). Clinical Evidence (Online), pii, 1304.
  47. Pasqualotto, A. C. & Denning, D.W. (2008). New and emerging treatments for fungal infections. The Journal of Antimicrobial Chemotherapy, 61, i19–i30.
  48. Petit, S. (2003). Pooled estimate of world leukoplakia prevalence: A systemic review. Oral Oncology, 39, 770–780
  49. Pienaar, E.D., Young, T., & Holmes, H. (2006). Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database of Systematic Reviews (Online), 19, 3, CD003940.
  50. Pigatto, P.D. & Guzzi, G. (2005). Oral lichenoid lesions: more than mercury. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endontics, 100, 398–400.
  51. Preetha, A., & Banerjee, R. (2005). Comparison of Artificial Saliva Substitutes. Trends in Biomaterials & Artificial Organs, 18, 178–186.
  52. Scully, C. (Ed.). (2008). In: Oral and Maxillofacial Medicine: The Basis of Diagnosis and Treatment. London: Churchill Livingstone/Elsevier.
  53. Scully, C. & Bagan, J.V. (2004). Adverse drug reactions in the orofacial region. Critical Reviews in Oral Biology and Medicine, 15, 221–139.
  54. Scully, C., & Felix, D.H. (2005). Oral medicine: Update for the dental practitioner – Dry mouth and disorders of salivation. British Dental Journal, 199, 423–427.
  55. Seymour, R.A. & Rudralingham, M. (2008). Oral and dental adverse drug reactions. Periodontology 2000, 46, 9–26.
  56. Sulieman, M. (2005) An overview of tooth discoloration: Extrinsic, intrinsic and internalized stains. Dental Update, 32, 463–464, 466–468, 471.
  57. Sumanth, S., Bhat, K.M., & Bhat, G.S. (2007). Clinical management of an unusual case of gingival enlargement. The Journal Contemporary Dental Practice, 8, 88–94.
  58. Tredwin, C.J., Scully, C., & Bagan-Sebastian, J.V. (2005). Drug-induced disorders of teeth. Journal of Dental Research, 84, 596–602.
  59. Vañó-Galván, S. & Jaén, P. (2008). Black hairy tongue. Cleveland Clinic Journal of Medicine, 75, 847–848.
  60. Vieillard, M.H., Maes, J.M., Penel, G., Facon, T., Magro, L., & Bonneterre, J., et al. (2008). Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine, 75, 34–40.
  61. Volpato, L.E., Silva, T.C., Oliveira, T.M., Sakai, V. T., & Machado, M.A. (2007). Radiation therapy and chemotherapy-induced oral mucositis. Revista Brasileira de Otorrinolaringologia, 73, 562–568.
  62. Weinstein, I. & Rosencrans M. (1962). Treatment of black hairy tongue with triamcinolone acetonide. Report of a case. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics, 15, 1071–1074.
  63. Worthington, H.V., Clarkson, J.E., & Eden, O.B. (2007). Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Review, 217, CD000978.
  64. Yarom, N., Yahalom, R., Shoshani, Y., Hamed, W., Regev, E., & Elad, S. (2007). Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporosis International, 18, 1363–1370.